Kamada (NASDAQ:KMDA) Stock Breaks Above Two Hundred Day Moving Average – Should You Sell?

Kamada Ltd. (NASDAQ:KMDA)’s share price passed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $8.00 and traded as high as $8.14. Kamada shares last traded at $8.10, with a volume of 206,789 shares trading hands.

Trending Headlines about Kamada

Here are the key news stories impacting Kamada this week:

• Positive Sentiment: Kamada raised its 2026 revenue guidance to $205 million–$208 million and said it expects double-digit revenue and profitability growth in 2027. The company also reported record-high results for the first nine months of 2026. Company results and outlook
• Positive Sentiment: A three-year, $50 million U.S. source-plasma supply agreement adds a significant contract and supports growth prospects. Plasma supply deal
• Positive Sentiment: Third-quarter earnings were $0.14 per share, topping the $0.13 consensus and rising from $0.09 a year earlier. Stifel also raised its price target to $12. Earnings beat Stifel price target
• Positive Sentiment: The company declared a special cash dividend of $0.14 per share, offering a near-term shareholder return. Shareholders of record November 19 are scheduled to be paid December 9. Dividend announcement
• Negative Sentiment: Third-quarter revenue was $52.03 million, slightly below analysts’ $52.51 million estimate, limiting the strength of the earnings beat.

Analysts Set New Price Targets

Several analysts have weighed in on KMDA shares. Weiss Ratings cut shares of Kamada from a “buy (b)” rating to a “buy (b-)” rating in a research note on Monday. UBS Group restated a “buy” rating and set a $15.00 target price on shares of Kamada in a research report on Friday, September 18th. William Blair set a $15.00 target price on shares of Kamada in a report on Tuesday, July 21st. Wall Street Zen upgraded shares of Kamada from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 15th. Finally, Benchmark reiterated a “buy” rating on shares of Kamada in a research report on Tuesday, July 21st. Four analysts have rated the stock with a Buy rating. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $13.75.

Kamada Price Performance

The company has a market cap of $465.83 million, a price-to-earnings ratio of 18.84, a price-to-earnings-growth ratio of 0.64 and a beta of 0.90. The business’s fifty day moving average price is $8.06 and its 200 day moving average price is $8.00.

Kamada (NASDAQ:KMDA) last issued its quarterly earnings data on Monday, November 9th. The biotechnology company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.01. The company had revenue of $52.03 million for the quarter, compared to analysts’ expectations of $52.51 million. Kamada had a net margin of 12.67% and a return on equity of 9.38%. As a group, equities research analysts anticipate that Kamada Ltd. will post 0.48 EPS for the current year.

Kamada Dividend Announcement

The business also recently declared a special dividend, which will be paid on Wednesday, December 9th. Shareholders of record on Thursday, November 19th will be given a $0.14 dividend. The ex-dividend date is Thursday, November 19th. Kamada’s payout ratio is 34.21%.

Institutional Investors Weigh In On Kamada

Several institutional investors and hedge funds have recently made changes to their positions in KMDA. Aristides Capital LLC raised its position in shares of Kamada by 4.5% during the first quarter. Aristides Capital LLC now owns 34,491 shares of the biotechnology company’s stock worth $288,000 after acquiring an additional 1,476 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in shares of Kamada by 14.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,527 shares of the biotechnology company’s stock worth $92,000 after acquiring an additional 1,346 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in Kamada in the third quarter valued at approximately $25,000. Institutional investors and hedge funds own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company focused on the development, manufacturing and commercialization of plasma-derived therapeutics and specialty pharmaceutical products. The company uses its expertise in plasma protein purification to address rare diseases, immune deficiencies and other serious medical conditions. Kamada’s portfolio includes GLASSIA, an intravenous alpha-1 antitrypsin therapy used as augmentation treatment for adults with severe alpha-1 antitrypsin deficiency and emphysema.